Adaptive Immune Response Platform for Diverse Disease Treatment

The inventive concept leverages the core technology of the original patent to develop novel applications in treating respiratory diseases, preventing influenza, and addressing neurodegenerative and cardiovascular diseases, as well as preventing HIV.

The original patent focused on treating bladder cancer using Bacillus Calmette-Guerin (BCG) and antigen presenting cells. However, the current inventive concept expands this technology to tackle a broader range of diseases, addressing the limitations of the original patent in terms of disease scope and treatment options.

The inventive concept revolves around administering vaccine compositions comprising immunotherapeutic primed antigen presenting cells and IL-15:IL-15Rα fusion protein complexes to subjects with diverse diseases. These compositions stimulate or enhance immune responses to specific disease-causing pathogens or agents, thereby providing a therapeutic effect. The antigen presenting cells are isolated from subjects with the respective diseases, and the IL-15:IL-15Rα fusion protein complex is tailored to stimulate an immune response specific to each disease.

The new claims introduce a paradigm shift in applying the core technology to entirely new disease areas, including respiratory diseases, influenza, neurodegenerative diseases, cardiovascular diseases, and HIV prevention. This inventive step lies in the recognition that the original technology can be adapted to address a wide range of diseases, leveraging the flexibility of the antigen presenting cells and IL-15:IL-15Rα fusion protein complex.

Alternative embodiments may include modifying the antigen presenting cells or IL-15:IL-15Rα fusion protein complex to target specific disease subtypes or using different routes of administration. Variations may also involve combining the vaccine compositions with other immunotherapies or adjuvants to enhance treatment efficacy.

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, targeting a broad range of diseases with high unmet medical needs. The market potential spans across multiple therapeutic areas, including respiratory, infectious, neurodegenerative, and cardiovascular diseases, as well as HIV prevention.